Home Tags Loncastuximab tesirine

Tag: loncastuximab tesirine

Featured Image: Multiple microscopic slides with stained blood smears, ready for testing. Courtesy: © Fotolia. Used with permission.

First Patients Dosed with Combination of Loncastuximab Tesirine + Ibrutinib in...

Diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) are two distinct subtypes of non-Hodgkin lymphoma (NHL). These hematological malignancies are associated with...
New York Stock Exchange (released under Public Domain license. Photo courtesy 2020 Jean Beaufort.

ADC Therapeutics Completes U.S. $ 267 Million Initial Public Offering

Earlier today, New Ventures Funds, a venture fund targeting investments in companies across healthcare and life sciences, confirmed that ADC Therapeutics (Lausanne; Biopôle, Switzerland),...
Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Pivotal Phase II Clinical Trial of Single Agent Loncastuximab Tesirine in...

Results from a pivotal 145-patient Phase II clinical trial of loncastuximab tesirine (ADCT-402; ADC Therapeutics) for the treatment of relapsed or refractory diffuse large...
Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Loncastuximab Tesirine Shows Early Promise in Patients with Relapsed/Refractory B-cell Non-Hodgkin...

Loncastuximab tesirine, also known as ADCT-402, an investigational antibody-drug conjugate being developed by ADC Therapeutics, showed signs of clinical activity in patients with relapsed/refractory...
Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Freenome Enters Biomarker Development Collaboration with ADC Therapeutics

Swiss-based ADC Therapeutics, an oncology-drug development company specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotech company pioneering the a...

SOPHiA Genetics and ADC Therapeutics Partner for Biomarker Discovery in Pivotal...

ADC Therapeutics and SOPHiA GENETICS have entered into a collaboration to identify genomic markers associated with clinical response to loncastuximab tesirine (ADCT-402), an antibody...

15th ICML: Loncastuximab Tesirine Shows Significant Activity in R/R Diffuse Large...

Loncastuximab tesirine (ADCT‐402), an anti‐CD19 antibody‐drug conjugate (ADC) conjugated via a protease cleavable linker to SG3199, a highly cytotoxic DNA minor groove interstrand cross-linking...

What is Pyrrolobenzodiazepine (PBD)?

Structure of Pyrrolobenzodiazepine Pyrrolobenzodiazepine (PBD) Chemical Name: Diazepinoindole; Molecular Formula: C14H14N2O3 Molecular weight: 258,27 g/mole Average mass: 181.193 Da Monoisotopic mass: 181.063995 DaIntroduction Discovered in 1963, the pyrrolobenzodiazepines (PBDs) are a class of...
Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

First DLBCL Patient Dosed in Trial with Loncastuximab Tesirine

Swiss-base ADC Therapeutics, an oncology drug discovery and development company specializing in the development of proprietary antibody-drug conjugates (ADCs) targeting hematological malignancies and solid...